| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919838 | Radiotherapy and Oncology | 2011 | 4 Pages |
Abstract
In MSCC reirradiation was safe and effective. Patient walking capacity before reirradiation was the strongest prognostic factor for functional outcome. Reirradiation was given in about one-half of patients with in-field recurrence and different doses and fractionations were used, even though cumulative BED was in all cases ⩽120 Gy2.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ernesto Maranzano, Fabio Trippa, Michelina Casale, Paola Anselmo, Romina Rossi,